Module 5 Presentations

05/07/2024

CTR : Disclosure considerations

The EU database “shall be publicly available unless one or more exceptions apply” (Art. 81) These exceptions are: a) protecting personal data (PD) in accordance with Regulation (EC) No 45/2001; b) protecting commercially confidential information (CCI), in particular through taking into account the status of the marketing authorisation for the medicinal product, unless there is an overriding public interest in disclosure; c) protecting confidential communication between Member States in relation to the preparation of the assessment report; d) ensuring effective supervision of the conduct of a clinical trial by Member States Only data and information defined in the Regulation as being submitted via the portal and/or stored in the database shall be held in that database and subject to the disclosure rules set out in the Regulation. Check the CTS Transparency Rules (EMA/263067/2023) endorsed by EMA Management Board and published on 05Oct2023 here

The Organisation for Professionals in Regulatory Affairs

Regulatory requirements for CTs – EU (Jul2024)

27

Category 1: Phase I, Bioequivalence, Bioavailability and biosimilar trials Category 2: Phase II and III trials Category 3: Phase IV and LICT

CTR : New Transparency Rules

Source: CTIS transparency rules: quick guide for users (EMA) here

The Organisation for Professionals in Regulatory Affairs

Regulatory requirements for CTs – EU (Jul2024)

28